BioCentury
ARTICLE | Clinical News

Tendoncel: Phase II data

July 13, 2015 7:00 AM UTC

A double-blind, placebo-controlled Phase II trial in 34 patients with chronic grade 3 lateral epicondylitis showed that once-daily topical Tendoncel for 21 days significantly improved DASH scores by 7...